Aselizumab is a humanized IgG4 monoclonal antibody targeting L-selectin (CD62L), which is a cell adhesion molecule expressed on circulating neutrophils and regulates the chemotaxis of migratory cells to sites of injury; it may be associated with increased post-traumatic infection rates and leukopenia.